Armata Pharmaceuticals’ (ARMP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a research report report published on Thursday,Benzinga reports. They currently have a $7.00 price objective on the stock.

Armata Pharmaceuticals Price Performance

ARMP stock opened at $1.95 on Thursday. The stock has a market capitalization of $70.55 million, a PE ratio of -1.19 and a beta of 0.78. Armata Pharmaceuticals has a 1-year low of $1.89 and a 1-year high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.